↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Horak Friedrich) "

Sökning: WFRF:(Horak Friedrich)

Resultat 1-2 av 2

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	2017 swepub:Mat__t
2.	Pauli, Gabrielle, et al. (författare) Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. 2008 Ingår i: The Journal of allergy and clinical immunology. - : Elsevier BV. - 1097-6825 .- 0091-6749. ; 122:5, s. 951-60 Tidskriftsartikel (refereegranskat)abstract BACKGROUND: Recombinant DNA technology has the potential to produce allergen-specific immunotherapy vaccines with defined composition. OBJECTIVE: To evaluate the effectiveness of a new recombinant birch pollen allergen vaccine in patients with birch pollen allergy. METHODS: A multicenter, randomized, double-blind, placebo-controlled trial was undertaken to compare the following 3 vaccines in 134 adults with birch pollen allergy: recombinant birch pollen allergen vaccine (rBet v 1a), licensed birch pollen extract, natural purified birch pollen allergen (nBet v 1), and placebo. Patients received 12 weekly injections followed by monthly injections of the maintenance dose containing 15 microg Bet v 1 for 2 years. RESULTS: Significant reductions (about 50%) in rhinoconjunctivitis symptoms (rBet v 1, P = .0002; nBet v 1, P = .0006; birch extract, P = .0024), rescue medication (rBet v 1, P = .0011; nBet v 1, P = .0025; birch extract, P = .0063), and skin sensitivities (P < .0001) were observed in the 3 actively treated groups compared with placebo during 2 consecutive pollen seasons. Clinical improvement was accompanied by marked increases in Bet v 1-specific IgG levels, which were higher in the rBet v 1-treated group than in the birch and nBet v 1-treated groups. New IgE specificities were induced in 3 of 29 patients treated with birch pollen extract, but in none of the 32 rBet v 1-treated or 29 nBet v 1-treated patients. No severe systemic adverse events were observed in the rBet v 1-treated group. CONCLUSION: The rBet v 1-based vaccine was safe and effective in treating birch pollen allergy, and induced a highly specific immune response.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-2 av 2

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (1)

Typ av innehåll: refereegranskat (1)

Författare/redaktör: Chen, C. (1); Chen, S. (1); Chen, X. (1); Chen, Y. (1); Deluca, C. (1); Endo, M. (1); visa fler...; Garcia, C. (1); Hayashi, T. (1); Hirose, M. (1); Hu, D. (1); Jackson, M. (1); Kim, H. (1); Kobayashi, T. (1); Li, B. (1); Li, L. (1); Liu, B. (1); Liu, D. (1); Liu, L. (1); Nakamura, T. (1); Ninomiya, Y. (1); Okumura, Y. (1); Sanchez, J. (1); Sasaki, Y. (1); Shimizu, S. (1); Sun, X. (1); Suzuki, Y. (1); Takahashi, Y. (1); Tanaka, S. (1); Vogel, M. (1); Wang, C. (1); Wang, F. (1); Wang, R. (1); Wu, X. (1); Yamamoto, S. (1); Yang, H. (1); Yang, Y. (1); Zhang, J. (1); Zhu, J. (1); Zhu, Y. (1); Kim, Y. (1); Zhang, R. (1); Zhao, Y. (1); Banerjee, P. (1); Gosselink, M. (1); Kanno, T. (1); Watanabe, I. (1); Gonzalez, S. (1); Suzuki, S (1); Banerjee, S. (1); Rodriguez, D. (1); visa färre...

Lärosäte: Göteborgs universitet (1); Karolinska Institutet (1)

Språk: Engelska (2)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy